EP Bold Solutions | Abbott
CARDIOVASCULAR
hamburger
EP Bold Solutions

AFib is a growing crisis in Electrophysiology (EP). This condition affects more than 37 million people.1 We create bold solutions to challenge AFib. This is a suite technology that boldly redefines the EP Lab. Clinical support that elevates your practice to meet today’s challenges. It is a partnership to drive impact and grow the EP community.
 

FROM 37 MILLION TODAY, TO MORE THAN 60 MILLION BY 2050

EP Bold Solutions

INNOVATE

Technology that boldly
redefines the EP Lab

Innovate

ELEVATE

Clinical support that elevates your
practice to meet today's challenges

Elevate

IMPACT

Partnerships that drive
impact for the EP community

Impact

 

Only Abbott Offers a Holistic EP Portfolio

Portfolio

References

  1. Go A, Hylek E, Phillips K, Chang Y, et al. Prevalence of Diagnosed Atrial Fibrillation in Adults: National implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors In Atrial Fibrillation (ATRIA) Study. JAMA. 2001; 285(18): 2370-5. https://jamanetwork.com/journals/jama/fullarticle/193807

MAT-2208730 v1.0

DO YOU WISH TO CONTINUE AND EXIT CARDIOVASCULAR.ABBOTT?

CONTENTS OF THE SITE ARE NOT UNDER THE CONTROL OF ABBOTT.

False
accessibility
© 2021 Abbott. All Rights Reserved. Please read the Legal Notice for further details.

Unless otherwise specified, all product and service names appearing in this Internet site are trademarks owned by or licensed to Abbott, its subsidiaries or affiliates. No use of any Abbott trademark, trade name, or trade dress in this site may be made without the prior written authorization of Abbott, except to identify the product or services of the company.

accessibility

DO YOU WISH TO CONTINUE AND EXIT CARDIOVASCULAR.ABBOTT?

CONTENTS OF THE SITE ARE NOT UNDER THE CONTROL OF ABBOTT.